Business Wire

PUUSTELLI-GROUP

19.3.2020 09:28:05 CET | Business Wire | Press release

Share
Puustelli Group: Water-resistant Biocomposite for Puustelli Bathroom Fittings

Puustelli has innovated a unique furniture system to eliminate moisture problems in bathroom fittings. The furniture frames feature a structure made of biocomposite by injection moulding. The biocomposite is a mixture of polypropylene and chemical pulp fibre, and is a water-resistant, non-toxic, ecological, modifiable and lasting material. This Finnish product innovation has been developed and is made 100% in Finland. The furniture system, which is suitable for kitchen furniture, has been in production in Puustelli Miinus kitchens since back in 2013. Puustelli was granted a European patent for its invention in 2018.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200319005234/en/

Water-resistant material
Most bathroom fittings typically have a frame of MDF or particleboard, both of which have poor moisture resistance. The biocomposite frame in Puustelli bathroom fittings can fully withstand water and comes with a 30-year guarantee.

Low-emission concept
Formaldehyde is also present in the panel materials typically used in bathroom fittings. When emitted into the indoor air, formaldehyde is harmful to the health. Even when the panel structure is only slightly damaged, the impact of moisture multiplies the harmful effects. The Puustelli biocomposite frame has a formaldehyde content of exactly 0%. Not only that, the biocomposite is antistatic and does not attract dust.

Ecological solution
Once a frame made from conventional furniture board has absorbed moisture, it can no longer be repaired and must be disposed of and replaced. The Puustelli biocomposite frame on the other hand is a fully reusable and recyclable material. Since it is recyclable, any waste raw material originating in the manufacturing process of the Puustelli biocomposite frame can be efficiently reused.

Puustelli bioframe can be modified
Unlike traditional frame materials, the Puustelli bioframe doesn’t tire of modification or being moved. The frame has precise dimensional accuracy and fittings and materials that affect its appearance can be switched around numerous times if required without the screw fastenings becoming fatigued. The furniture is available for large and small spaces alike. The frames can be finished in various ways depending on the range. Puustelli has also developed from the composite for the frame, a design end panel with a restrained pattern suitable for different styles. Small locators have also been made in the panel in conjunction with injection moulding to make it easy to screw the end panel accurately into the ready-made holes in the frame. The bioframes of the washbasin cupboards have been designed for careful use of space. Plumbing has also been taken into account and if necessary can easily be accessed later. Base cabinets come at a height of 613 mm and widths vary between 200 mm and 1200 mm depending on the model. Since the depth is just 370 mm, they can fit into small spaces.

“The bathroom product development process has been long and at times challenging, but the outcome was well worth all the work. Following our kitchen furniture, a similar bathroom fitting innovation was already anticipated and is now in production,” says Jussi Aine, CEO, Puustelli Group Oy. 

Puustelli Group Oy is a Finnish family enterprise and part of the century-old Harjavalta Group, which also includes Kastelli Group Oy and Lapti Group Oy. The Group had a turnover of €491 million in 2019.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye